Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1531 of 5804
-
Can Opioid-Free anesthesia stop chronic pain after breast cancer surgery?
Symptom relief Recruiting nowIn 230 patients undergoing mastectomy, the investigators will compare opioid-free anesthesia (OFA) versus conventional opioid-based anesthesia in terms of chronic pain. The enrolled patients will be randomly assigned into two groups with 1:1 ratio. Chronic pain will be evaluated …
Phase: NA • Sponsor: Gangnam Severance Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 07:59 UTC
-
Could less chemo mean better quality of life for bladder cancer patients?
Disease control Recruiting nowThis is an adaptive, open-label, randomised phase II trial that aims to evaluate the impact of 3 vs 6 cycles of first-line platinum-based chemotherapy followed by maintenance avelumab in the quality of life of patients with locally advanced or metastatic urothelial cancer. Initia…
Phase: PHASE2 • Sponsor: Queen Mary University of London • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New dosing strategy for myasthenia gravis drug shows promise
Disease control CompletedThe purpose of this open-label study is to investigate the efficacy, safety, and tolerability of a continuous regimen of efgartigimod compared with a cyclic regimen in participants with Generalized Myasthenia Gravis (gMG). Participants will receive efgartigimod throughout the st…
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Less invasive needle treatment could rival surgery for liver tumors
Disease control Ongoing230 patients with colorectal cancer liver metastases will be randomly assigned to resection or thermal ablation.
Phase: NA • Sponsor: Oslo University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New hope for myelofibrosis patients: experimental drug KER-050 enters phase 2 trial
Disease control Recruiting nowThe main aim of this study is to learn how safe elritercept is and how well it is tolerated when taken alone and in combination with the JAK inhibitor, ruxolitinib. Other aims are to learn about the effects of elritercept on the signs and symptoms of MF when taken with or without…
Phase: PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
One shot of radiation may control central lung cancer
Disease control OngoingThe purpose of this study is to determine if a single treatment of targeted radiation (called SBRT or Stereotactic Body Radiation Therapy) can be as safe and effective as multiple doses of radiation in patients with central non-small cell lung cancer
Phase: NA • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug combo shows promise against rare eye cancer
Disease control OngoingThis research study is investigating Binimetinib and Belinostat in participants with metastatic uveal melanoma. The research study will test the study drugs to see if the combination of binimetinib and belinostat can make tumors shrink or stop growing.
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Blood test may spot hidden cancer DNA after surgery
Knowledge-focused OngoingThe CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Maximum duration of participant participation is up to seven years from enrollment to study completion with up to five years of acti…
Sponsor: Exact Sciences Corporation • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
New combo therapy aims to delay ovarian cancer return
Disease control OngoingThis prospective, multicenter, open-label, randomized phase II maintenance study is evaluating the efficacy of UV1-olaparib-durvalumab combination as maintenance therapy after platinum combination therapy for BRCAwt patients with relapsed ovarian cancer.
Phase: PHASE2 • Sponsor: Nordic Society of Gynaecological Oncology - Clinical Trials Unit • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New data strategy aims to boost HIV suppression in underserved communities
Disease control OngoingThe Ryan White HIV/AIDS Program (RWHAP) for low-income people with HIV (PWH) is a key resource for reducing HIV health disparities and scaling up evidence-based interventions. As RWHAP serves \>50% of US PWH, RWHAP outcomes are vital to achieving "getting-to-zero"/ Ending the HIV…
Phase: NA • Sponsor: City University of New York • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New radiation combo aims to boost immunotherapy in advanced lung cancer
Disease control OngoingThis pilot phase I trial aims to investigate the safety and tolerability of low dose radiotherapy (LDRT) and concurrent partial stereotactic body radiation therapy (SBRT) in combination with programmed cell death-1 (PD-1) inhibitors in Stage IV non-small cell lung cancer (NSCLC) …
Phase: PHASE1 • Sponsor: Sichuan University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New combo aims to keep lung cancer from returning in the chest
Disease control Recruiting nowInvestigate the role of consolidative radiotherapy treatment at the thoraco-mediastinal level in the patient suffering from lung microcytoma - extensive disease and treated with chemo-immunotherapy with atezolizumab, in association with maintenance therapy with atezolizumab.
Phase: PHASE2 • Sponsor: Regina Elena Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
App helps men at risk for HIV test themselves and get linked to care
Prevention CompletedThis 5-year project will test an mobile health approach to improve HIV self-testing (HST) and linkage to HIV-related care among high-risk men in China. HIV-negative men who have sex with men (MSM) will be randomly assigned to an intervention group: access to WeTest-WeLink (a mobi…
Phase: NA • Sponsor: Emory University • Aim: Prevention
Last updated Jun 27, 2026 14:02 UTC
-
Smartphone program aims to help HIV patients kick the habit
Disease control OngoingThis study will evaluate if Automated Treatment performs better, in terms of facilitating long-term smoking abstinence, than the more resource-intensive Standard Treatment.
Phase: NA • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New digital platform aims to catch Alzheimer's before symptoms worsen
Diagnosis Recruiting nowThe aging population in Europe is leading to an increase in neurodegenerative diseases, such as Alzheimer's disease (AD), which is expected to affect 152 million people worldwide by 2050. In Italy, there are approximately 1.2 million cases of dementia, with 600,000 attributed to …
Sponsor: IRCCS San Raffaele • Aim: Diagnosis
Last updated Jun 27, 2026 08:12 UTC
-
New pill combo shows promise for older myeloma patients
Disease control OngoingThis is a phase II, multicenter, open-label study to evaluate the rate of patients achieving very good partial response (VGPR) or better to the oral combination Iberdomide Ixazomib Dexamethasone in elderly patients with multiple myeloma at first relapse . The patient population …
Phase: PHASE2 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New radiation approach could cut treatment time for rare skin cancer
Disease control Recruiting nowThis phase II trial tests whether hypofractionated radiation works to treat patients with Merkel cell carcinoma. Radiation therapy uses high energy radio waves to kill cancer cells and shrink tumors. Hypofractionated radiation therapy delivers higher doses of radiation therapy ov…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Dutch study tracks COVID antivirals in High-Risk patients
Knowledge-focused CompletedNovel antiviral drugs can mark a turning point in the prevention and treatment of patients with Covid-19. Recently, several independent large phase-III RCTs have shown that the intravenous administration of one gift of neutralizing SARS-CoV-2 monoclonal antibodies can reduce the …
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
New drug combo aims to shrink hard-to-treat tumors
Disease control Recruiting nowThis is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (dou…
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Could a menopause drug combo cut breast cancer risk?
Prevention OngoingWomen at risk for development of breast cancer and experiencing vasomotor menopausal symptoms (hot flashes) will be randomized to bazedoxifene (BZA) plus conjugated estrogens (CE) for 6 months versus a wait list control. Two risk factors for development of breast cancer will be s…
Phase: PHASE2 • Sponsor: University of Kansas Medical Center • Aim: Prevention
Last updated Jun 27, 2026 07:56 UTC